Altimmune, Inc. — Form 8-K Summary
Filing and event date: September 24, 2026; the report was signed on September 29, 2026. This is an officer appointment notice, not a periodic financial report.
Business context and reporting period
Altimmune is a Delaware-incorporated company with common stock listed on Nasdaq under ALT. The filing does not report results for a financial reporting period.
Financial position and performance
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material change
The Board appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. Gregory Weaver remains Chief Financial Officer.
Menziuso has 28 years of finance and accounting experience, including roles at Centessa Pharmaceuticals, Thermo Fisher Scientific, and Axovant Gene Therapies. The company will enter into an indemnification agreement with him in substantially the same form as its other executive officers’ agreements.
Other disclosures and investor verification
- The filing states there are no appointment-related arrangements with other persons, no relevant family relationship, and no material interest in transactions reportable under Item 404(a) of Regulation S-K.
- Verify the appointment’s effective date and whether subsequent filings disclose changes to the finance or accounting leadership team.
- Review the indemnification agreement when available for its terms.